Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2021-01-05 M&A Activity
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Selvita completes acquisition of Fidelta from Galapagos
M&A Activity Classification · 99% confidence The document is a press release dated January 4, 2021, announcing the completion of an acquisition (Selvita acquiring Fidelta from Galapagos). This type of announcement, detailing a significant corporate transaction like a merger or acquisition, aligns best with the M&A Activity category (TAR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a general regulatory announcement (RNS). Since it explicitly details a takeover/acquisition event, TAR is the most precise fit.
2021-01-05 English
6-K Filing
Regulatory Filings
2021-01-05 English
CORRECTIE EN VERVANGING - Galapagos’ CEO doneert €10 miljoen in de vorm van persoonlijke aandelen aan African Parks
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that the CEO of Galapagos is donating €10 million worth of personal shares to African Parks. This involves a transaction in the CEO's personal holdings of company stock, which is a form of insider transaction or director's dealing, even though the primary purpose is charitable donation. The key elements are the CEO's personal share transfer. This aligns best with the 'Director's Dealing' category (DIRS), which covers reports of personal share transactions by directors and executives. It is not a formal regulatory filing like a 10-K or an earnings release, but a specific corporate announcement regarding insider activity.
2020-12-24 Dutch
Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks
Environmental & Social Information Classification · 99% confidence The document announces a significant personal donation made by the CEO, Onno van de Stolpe, in the form of company shares to an external non-profit organization (African Parks). This transaction involves an executive dealing in the company's shares, even though it is a donation rather than a direct open-market purchase or sale. This type of insider transaction disclosure falls under the category of Director's Dealing (DIRS) or potentially a transaction in own shares (POS). However, since the core event is the executive's personal transaction involving company stock, 'Director's Dealing' (DIRS) is the most specific fit for reporting executive share movements. It is not a standard earnings release, capital change, or general regulatory filing.
2020-12-24 English
Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks
Major Shareholding Notification Classification · 99% confidence The document announces a personal transaction by the CEO of Galapagos, Onno van de Stolpe, involving the donation of €10 million worth of ordinary shares to African Parks over five years. This action constitutes a report of personal share transactions by a company director/executive, which directly aligns with the definition of 'Director's Dealing' (DIRS). Although it involves a donation, the core event is the transfer of shares by an insider.
2020-12-24 English
Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib)
Regulatory Filings Classification · 95% confidence The document is a press release dated December 15, 2020, announcing a revision to the commercialization and development agreement between Gilead Sciences and Galapagos NV regarding the drug Jyseleca (filgotinib). It details strategic changes following an FDA meeting, financial considerations (€160 million payment, royalty changes), and governance procedures related to the transaction between related parties. This type of announcement, detailing significant business/strategic changes, partnership restructuring, and financial implications, is characteristic of a major corporate disclosure. Since it is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI), and it is a formal announcement of a significant business event rather than a general regulatory filing fallback (RNS), the most appropriate classification is 'Capital/Financing Update' (CAP) due to the substantial financial restructuring and transfer of rights, or potentially 'Regulatory Filings' (RNS) if the focus is purely on the announcement nature. However, given the detailed financial terms and the restructuring of a major asset's commercial rights, 'CAP' is a strong fit, but 'RNS' is often used for press releases announcing material non-financial/non-earnings strategic shifts. Since the core event is a major contractual/financial realignment, and it is not explicitly a fundraising event (CAP), 'RNS' (Regulatory Filings - the general category for material announcements not covered elsewhere) is the safest classification for a press release detailing a strategic partnership change, especially since it contains 'gereglementeerde informatie' (regulated information). Given the options, and the nature of the announcement being a material corporate event disclosure, RNS is the best fit as a catch-all for significant, non-standard disclosures.
2020-12-16 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.